Genetic diagnostics leader Genedx has announced the appointment of Bryan Dechairo as its new Chief Operating Officer, effective immediately. Dechairo brings over 30 years of experience in exploratory and commercial diagnostic businesses, having most recently served as president and CEO of Sherlock Biosciences. He has also held executive leadership roles at prominent diagnostic and pharmaceutical companies, including Pfizer, Myriad Genetics, Assurex, and Medco Health.
In his new role, Dechairo will oversee product & technology, operations, medical affairs, innovation, and the program management teams at Genedx. His appointment comes at a critical time as the company aims to drive operational excellence and accelerate the adoption of genomic insights across healthcare.
Genedx, listed on the NASDAQ under the ticker symbol WGS, believes that everyone deserves personalized, targeted medical care and aims to translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies.
This appointment is expected to position Genedx for growth and scale as the company enters the next phase of commercial expansion. CEO and President Katherine Stueland expressed confidence in Dechairo’s ability to play a pivotal role in executing the company’s strategic vision and delivering impactful genomic insights to an increasing number of patients and families.
Dechairo’s appointment comes as the company seeks to leverage its world-class products, advanced AI, and exceptional talent to supercharge operational excellence and accelerate profitable growth, with the ultimate goal of leading the genomics revolution in healthcare. As a result of these announcements, the company's shares have moved -1.3% on the market, and are now trading at a price of $78.6. If you want to know more, read the company's complete 8-K report here.
